RMDNYSESurgical & Medical Instruments & ApparatusFiscal year ends June 30Also trades as RSMDF
RESMED INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 13, 2026
$239.77+0.80 (+0.33%)
Close on Oct 19, 2026
- Market cap
- $34.79B
- P/E (TTM)
- 23.0
- Dividend yield
- 1.00%
Share price
−$28.32 (−10.56%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
RESMED INC grew revenue 9.9% to $5.65B over the twelve months to Jun 30, 2026. Operating income rose 11.9% to $1.89B, moving the operating margin from 32.7% to 33.4%. Free cash flow was $1.65B, down 0.7% from a year earlier.
Revenue
$5.65B
+9.9% vs. a year earlier
Operating income
$1.89B
+11.9% vs. a year earlier
Free cash flow
$1.65B
-0.7% vs. a year earlier
EPS, diluted
$10.43
+9.7% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $34.79B
- P/E ratio
- 23.0
- Price to sales
- 6.15
- Price to book
- 5.28
- Dividend yield
- 1.00%
- Free cash flow yield
- 4.74%
Fundamentals
- Revenue
- $5.65B
- Net income
- $1.52B
- EPS, diluted
- $10.43
- Free cash flow
- $1.65B
- Book value per share
- $45.38
- Diluted shares
- 145M
Fifteen years at a glance
Fiscal years 2012 to 2026, USD
Revenue
$5.65B+9.9% YoY
Gross profit
$3.45B+13.0% YoY
Operating income
$1.89B+11.9% YoY
Net income
$1.52B+8.8% YoY
EPS, diluted
$10.43+9.7% YoY
Free cash flow
$1.65B-0.7% YoY
Reported period